ABSTRACT
This chapter presents a synopsis of the etiology, pathogenesis, and factors involved in triggering Crohn's disease. The justifications for the use of HSCT are described, based on experimental studies and on clinical studies and publications for the treatment of Crohn's disease with HSCT. Crohn's disease is recognized by the European Society for Blood and Marrow Transplantation (EBMT) as a clinical option for critically ill Crohn's Disease patients who are refractory to conventional drug treatment. This chapter discusses the perspectives and the future of HSCT in the treatment of Crohn's disease.
